Literature DB >> 11889188

Cortisol and 17-hydroxyprogesterone kinetics in saliva after oral administration of hydrocortisone in children and young adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Michael Gröschl1, Manfred Rauh, Helmuth G Dörr.   

Abstract

We have analyzed the kinetics of salivary cortisol (F) and 17-hydoxyprogesterone (17OHP) after a single oral administration of hydrocortisone (HC; 10 mg; 0700 h) in healthy male volunteers (n = 10; 18-29 yr) and in patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (males, n = 7; females, n = 3; 8.5-20.4 yr). The HC doses, related to body surface area, ranged from 6.3-9.2 mg/m(2) in controls and from 4.2-10.7 mg/m(2) in CAH patients. Saliva was collected over 5 h (at intervals of 15-30 min), and the steroids were measured with adapted RIAs. In healthy controls, maximal cortisol values (250.3 +/- 35.9 nmol/liter) were reached after 30 min. Values showed a monophasic decrease. A t(1/2) of 94.5 min was calculated. The proportion of the HC dose in the total area under the curve was 71.2 +/- 3.2%. For 17OHP, a monophasic decrease was found, with a minimum level of 48 +/- 27 pmol/liter after 300 min. In CAH patients the salivary steroid profiles showed individual kinetics (maximal cortisol values ranged from 107-726 nmol/liter). Here a monophasic decrease was found with a shorter t(1/2) of 56.4 min. The HC dose proportion in the area under the curve was 88.3 +/- 6%. 17OHP showed biphasic courses with a decrease to the minimum 17OHP level after 210 min at the latest and a subsequent gradual increase. Our findings of limited normalization of the adrenal cortex by oral HC administration underlines the necessity of optimizing therapy control and indicates the usefulness of kinetic studies for the judgement of therapy in CAH patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11889188     DOI: 10.1210/jcem.87.3.8297

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Anterior pituitary hormone replacement therapy--a clinical review.

Authors:  Christoph J Auernhammer; George Vlotides
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 2.  Progress in molecular-genetic studies on congenital adrenal hyperplasia due to 11beta-hydroxylase deficiency.

Authors:  Li-Qiang Zhao; Su Han; Hao-Ming Tian
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

3.  The clinical and biochemical spectrum of congenital adrenal hyperplasia secondary to 21-hydroxylase deficiency.

Authors:  Tony Huynh; Ivan McGown; David Cowley; Ohn Nyunt; Gary M Leong; Mark Harris; Andrew M Cotterill
Journal:  Clin Biochem Rev       Date:  2009-05

4.  Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children : validation of liquid chromatography tandem mass spectrometry method.

Authors:  Manfred Rauh; Daniel Stachel; Michaela Kuhlen; Michael Gröschl; Wolfgang Holter; Wolfgang Rascher
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Duration of suppression of adrenal steroids after glucocorticoid administration.

Authors:  John S Fuqua; Deborah Rotenstein; Peter A Lee
Journal:  Int J Pediatr Endocrinol       Date:  2010-03-31

6.  Genotyping of CYP21A2 for congenital adrenal hyperplasia screening using allele-specific primer extension followed by bead array hybridization.

Authors:  Yongtaek Oh; Sung Won Park; Sung-Min Chun; Namkyoo Lim; Ki Sup Ahn; Jong-Ok Ka; Dong-Kyu Jin; Byoung-Don Han
Journal:  Mol Diagn Ther       Date:  2009-12-01       Impact factor: 4.074

7.  Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.

Authors:  Miguel Debono; Ashwini Mallappa; Verena Gounden; Aikaterini A Nella; Robert F Harrison; Christopher A Crutchfield; Peter S Backlund; Steven J Soldin; Richard J Ross; Deborah P Merke
Journal:  Eur J Endocrinol       Date:  2015-09-04       Impact factor: 6.664

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.